Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actoxumab/bezlotoxumab - Merck & Co

Drug Profile

Actoxumab/bezlotoxumab - Merck & Co

Alternative Names: 3D8; Bezlotoxumab/actoxumab; CDA-1/CDA-2; GS-CDA-1/MDX-1388; MBL-CDA1/MBL-CDB1; MDX-066 + MDX-1388; MDX-066/MDX-1388; MK-3415 + MK-6072; MK-3415/MK-6072; MK-3415A

Latest Information Update: 24 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex; University of Massachusetts Medical School
  • Developer Bristol-Myers Squibb; Merck & Co; University of Massachusetts Medical School
  • Class Antidiarrhoeals; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Clostridium difficile infections

Most Recent Events

  • 24 Jan 2018 No recent reports on development identified - Phase-III for Clostridium difficile infections in Japan, Finland, Sweden, Poland, Greece, Belgium, Italy, Czech Republic, United Kingdom, Austria, Spain, Portugal, Denmark, Germany and USA (IV)
  • 20 Sep 2015 Merck announces intention to submit regulatory applications in USA, European Union and Canada in 2015
  • 20 Sep 2015 Efficacy and adverse events data from the phase III MODIFY I and II trials in Clostridium difficile infections released by Merck
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top